Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients

Given the recent approval of the first pan-genotypic chronic hepatitis C virus (HCV) therapy, managed care, health systems, and clinicians will need to evaluate current practices related to essential laboratory assessments used to select therapy. Historically, clinicians and payers required a batter...

Descripción completa

Detalles Bibliográficos
Autores principales: Calabrese, Martin J., Hynicka, Lauren M., de Bittner, Magaly Rodriguez, Shaya, Fadia T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Viewpoints
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398219/
https://www.ncbi.nlm.nih.gov/pubmed/29290175
http://dx.doi.org/10.18553/jmcp.2018.24.1.20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398219/
https://www.ncbi.nlm.nih.gov/pubmed/29290175
http://dx.doi.org/10.18553/jmcp.2018.24.1.20

Ejemplares similares